In re EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation, MDL No. 2785 (D. Kan. May 31, 2018)

Key Insight: third-party, relevancy, “objections lack support and do not adequately provide a basis for the Court to grant them”

Nature of Case: Antitrust, consumer protection, racketeering

Keywords: overbroad, unduly burdensome, boilerplate, quash

View Case Opinion

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

Copyright © 2022, K&L Gates LLP. All Rights Reserved.